Galena Biopharma (GALE) : The consensus on Galena Biopharma (GALE) based on 4 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
For the current week, the company shares have a recommendation consensus of Buy. Also, Raymond James downgrades its view on Galena Biopharma (NASDAQ:GALE) according to the research report released by the firm to its investors. The shares have now been rated Market Perform by the stock experts at the ratings house. Earlier, the shares had a rating of Outperform. The rating by the firm was issued on June 29, 2016.
Galena Biopharma (NASDAQ:GALE): The stock opened at $0.4 and touched an intraday high of $0.41 on Wednesday. During the day, the stock corrected to an intraday low of $0.395, however, the bulls stepped in and pushed the price higher to close in the green at $0.406 with a gain of 1.45% for the day. The total traded volume for the day was 2,008,270. The stock had closed at $0.4002 in the previous trading session.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.